ABSTRACT
Objectives:
In this study, it was aimed to examine the change in functioning impairment in patients diagnosed with attention deficit hyperactivity disorder (ADHD) after 1 year of follow-up and treatment, to evaluate the role of the type of medication used, and the effect of treatment on functionality.
Materials and Methods:
The data of the study were obtained by retrospectively scanning the files of patients aged 6-14 years, who were diagnosed with ADHD as a result of a semi-structured clinical interview in Kocaeli University Faculty of Medicine, Department of Child and Adolescent Psychiatry between September 2012 and December 2020, and who were eligible to be included in the study as a result of our exclusion criteria. The sociodemographic information of the patients was evaluated, the parent forms of the Weiss Functional Impairment Rating Scale-Parent Form (WFIRS-P) and the clinical global impressions scales (CGI), which are routinely given at the first admission and control appointments, were evaluated.
Results:
Data of 54 patients, 9 girls and 45 boys, were included in the study. It was determined that there was a significant improvement in the mean scores of the CGI scales after 1 year of regular follow-up and treatment. Significant improvements were also found in WFIRS-P total and various subscale scores, and it was observed that the improvements in functionality areas differed between age groups and drug types.
Conclusion:
ADHD is one of the most common reasons for admission to our departments and causes serious impairments in functionality. For this reason, it is important to evaluate the areas with impaired functionality. In terms of individualizing the treatment according to those areas and patients, it will be useful to determine the areas of impaired functioning needing treatment according to age groups and in which areas drug treatments are effective. There are limited studies in the literature addressing functioning in ADHD and further studies in this area are needed.
References
1American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders- Fifth Edition. (DSM-5). American Psychiatric Publishing, Arlington, VA 2013.
2Palermo TM, Long AC, Lewandowski AS, Drotar D, Quittner AL, Walker LS. Evidence-based assessment of health-related quality of life and functional impairment in pediatric psychology. J Pediatr Psychol. 2008;33:983-996.
3Loe IM, Feldman HM. Academic and educational outcomes of children with ADHD. J Pediatr Psychol. 2007;32:643-654.
4Johnston C, Mash EJ. Families of children with attention-deficit/hyperactivity disorder: review and recommendations for future research. Clin Child Fam Psychol Rev. 2001;4:183-207.
5Johnson RC, Rosen LA. Sports behavior of ADHD children. J of Atten Disorders. 2000;4:150-160.
6Haack LM, Gerdes AC. Functional impairment in Latino children with ADHD: implications for culturally appropriate conceptualization and measurement. Clin Child Fam Psychol Rev. 2011;14:318-328.
7Börekçi B. Okul öncesi çocuklarda dikkat eksikliği hiperaktivite bozukluğu belirtilerinin, davranışsal, sosyal problemler, aile işlevselliği ve ebeveyn tutumları ile ilişkilerinin değerlendirilmesi. Yayınlanmamış Yüksek Lisans Tezi. Sosyal Bilimler Enstitüsü, Işık Üniversitesi, İstanbul, 2017.
8Strine TW, Lesesne CA, Okoro CA, McGuire LC, Chapman DP, Balluz LS, Mokdad AH. Emotional and behavioral difficulties and impairments in everyday functioning among children with a history of attention-deficit/hyperactivity disorder. Prev Chronic Dis. 2006;3:A52.
9Barkley RA. Attention deficit hyperactivity disorder: A handbook for diagnosis and treatment (1sted). New York; Guilford Press; 1990:1-747.
10DuPaul GJ, McGoey KE, Eckert TL, VanBrakle J. Preschool children with attention-deficit/hyperactivity disorder: impairments in behavioral, social, and school functioning. J Am Acad Child Adolesc Psychiatry. 2001;40:508-515.
11Barkley RA. Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment (2nded). New York: GuilfordPress; 1998;1-628.
12Hinshaw SP. Academic underachievement, attention deficits, and aggression: Comorbidity and implications for intervention. J Consult Clin Psychol. 1992;60:893-903.
13Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, Ganiats TG, Kaplanek B, Meyer B, Perrin J, Pierce K, Reiff M, Stein MT, Visser S. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128:1007-1022.
14Barkley RA. Attention-Deficit Hyperactivity Disorder: A handbook for diagnosis and treatment (3rd ed). New York; Guilford Press; 2006:1-770.
15Spencer T, Biederman J, Wilens T. Nonstimulant treatment of adult attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27:373-383.
16Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894-921.
17Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010;19:353-364.
18Epstein JN, Langberg JM, Lichtenstein PK, Altaye M, Brinkman WB, House K, Stark LJ. Attention-deficit/hyperactivity disorder outcomes for children treated in community-based pediatric settings. Arch Pediatr Adolesc Med. 2010;164:160-165.
19Karpenko V, Owens JS, Evangelista NM, Dodds C. Clinically significant symptom change in children with attention-deficit/hyperactivity disorder: does it correspond with reliable improvement in functioning? J Clin Psychol. 2009;65:76-93.
20O'Connor BC, Garner AA, Peugh JL, Simon J, Epstein JN. Improved but still impaired: symptom-impairment correspondence among youth with attention-deficit hyperactivity disorder receiving community-based care. J Dev Behav Pediatr. 2015;36:106-114.
21Owens JS, Johannes LM, Karpenko V. The relation between change in symptoms and functioning in children with ADHD receiving school-based mental health services, School MentHealth. 2009;1:183-195.
22Gathje RA, Lewandowski LJ, Gordon M. The role of impairment in the diagnosis of ADHD. J Atten Disord. 2008;11:529-537.
23Gordon M, Antshel K, Faraone S, Barkley R, Lewandowski L, Hudziak JJ, Biederman J, Cunningham C. Symptoms versus impairment: the case for respecting DSM-IV's Criterion D. J Atten Disord. 2006;9:465-475.
24Angold A, Costello EJ, Farmer EM, Burns BJ, Erkanli A. Impaired but undiagnosed. J Am Acad Child Adolesc Psychiatry. 1999;38:129-137.
25Fabiano GA, Pelham WE Jr, Waschbusch DA, Gnagy EM, Lahey BB, Chronis AM, Onyango AN, Kipp H, Lopez-Williams A, Burrows-Maclean L. A practical measure of impairment: psychometric properties of the impairment rating scale in samples of children with attention deficit hyperactivity disorder and two school-based samples. J Clin Child Adolesc Psychol. 2006;35:369-385.
26Fabiano GA, Pelham WE. Measuring impairment in children with attention-deficit-hyperactivity disorder. ADHD Rep. 2002;10:6-10.
27Barkley RA, Fischer M, Smallish L, Fletcher K. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry. 2006;45:192-202.
28Scoggins JF, Patrick DL. The use of patient-reported outcomes instruments in registered clinical trials: evidence from ClinicalTrials.gov. Contemp Clin Trials. 2009;30:289-292.
29Tarakçıoğlu MC, Memik NÇ, Olgun NN, Aydemir Ö, Weiss MD. Turkish validity and reliability study of the Weiss Functional Impairment Rating Scale-Parent Report. Atten Defic Hyperact Disord. 2015;7:129-139.
30Guy W. ECDEU Assessment Manual forPsychopharmacology (028 Clinical Global Impressions [CGI]) Rockville, MD: NationalInstitutes of Health. 1976;218-222.
31Stein MA, Waldman ID, Charney E, Aryal S, Sable C, Gruber R, Newcorn JH. Dose Effects and Comparative Effectiveness of Extended Release Dexmethylphenidate and Mixed Amphetamine Salts, J Child Adolesc Psychopharmacol. 2011;21:581-586.
32Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, Michelson D; Atomoxetine/Methylphenidate Comparative Study Group. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008;165:721-730.
33Weiss M, Childress A, Mattingly G, Nordbrock E, Kupper RJ, Adjei AL. Relationship Between Symptomatic and Functional Improvement and Remission in a Treatment Response to Stimulant Trial. J Child Adolesc Psychopharmacol. 2018;28:521-529.
34Banaschewski T, Soutullo C, Lecendreux M, Johnson M, Zuddas A, Hodgkins P, Adeyi B, Squires LA, Coghill D. Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder. CNS Drugs. 2013;27:829-840.
35Banaschewski T, Johnson M, Lecendreux M, Zuddas A, Adeyi B, Hodgkins P, Squires LA, Coghill DR. Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder. CNS Drugs. 2014;28:1191-1203.
36Tarakcioglu MC, Caliskan Y, Kadak MT, Aliyev Okumus N, Aksoy UM, Tufan AE, Yildiz Gündoğdu O, Cakın Memik N, Weiss MD. Is Functional Improvement Always Correlated with Symptomatic Improvement in Children with Attention Deficit/Hyperactivity Disorder Managed with Oros Methylphenidate? A Prospective Open-Label Naturalistic Follow-Up Study, Psychiatry and Clinical Psychopharmacology. 2020;30:128-135.
37Fabiano GA, Pelham WE Jr, Coles EK, Gnagy EM, Chronis-Tuscano A, O'Connor BC. A meta-analysis of behavioral treatments for attention-deficit/hyperactivity disorder. Clin Psychol Rev. 2009;29:129-140.
38A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999;56:1073-1086.
39Eyberg SM, Nelson MM, Boggs SR. Evidence-based psychosocial treatments for children and adolescents with disruptive behavior. J Clin Child Adolesc Psychol. 2008;37:215-237.
40Pelham WE Jr, Fabiano GA. Evidence-based psychosocial treatments for attention-deficit/hyperactivity disorder. J Clin Child Adolesc Psychol. 2008;37:184-214.
41Garner AA, O'connor BC, Narad ME, Tamm L, Simon J, Epstein JN. The relationship between ADHD symptom dimensions, clinical correlates, and functional impairments. J Dev Behav Pediatr. 2013;34:469-477.
42Willcutt EG, Nigg JT, Pennington BF, Solanto MV, Rohde LA, Tannock R, Loo SK, Carlson CL, McBurnett K, Lahey BB. Validity of DSM-IV attention deficit/hyperactivity disorder symptom dimensions and subtypes. J Abnorm Psychol. 2012;121:991-1010.
43Cohen RA. The neuropsychology of attention. Plenum, New York, USA, Como PG; Springer US 1993:1-545.
44Gajria K, Kosinski M, Sikirica V, Huss M, Livote E, Reilly K, Dittmann RW, Erder MH. Psychometric validation of the Weiss Functional Impairment Rating Scale-Parent Report Form in children and adolescents with attention-deficit/hyperactivity disorder. Health Qual Life Outcomes. 2015;13:184.
45Danckaerts M, Sonuga-Barke EJ, Banaschewski T, Buitelaar J, Döpfner M, Hollis C, Santosh P, Rothenberger A, Sergeant J, Steinhausen HC, Taylor E, Zuddas A, Coghill D. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry. 2010;19:83-105.
46Young J. Common comorbidities seen in adolescents with attention-deficit/hyperactivity disorder. Adolesc MedState Art Rev. 2008;19:216-228.
47Riggs PD. Clinical approach to treatment of ADHD in adolescents with substance use disorders and conduct disorder. J Am Acad Child Adolesc Psychiatry. 1998;37:331-332.
48Wolraich ML, Hagan JF Jr, Allan C, Chan E, Davison D, Earls M, Evans SW, Flinn SK, Froehlich T, Frost J, Holbrook JR, Lehmann CU, Lessin HR, Okechukwu K, Pierce KL, Winner JD, Zurhellen W; Subcommittee on children and adolescents with attention- deficit/ hyperactivity disorder. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019;144:e20192528.
49Fuentes J, Danckaerts M, Cardo E, Puvanendran K, Berquin P, De Bruyckere K, Montoya A, Quail D, Escobar R. Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2013;33:766-774.
50Maziade M, Rouleau N, Lee B, Rogers A, Davis L, Dickson R. Atomoxetine and neuropsychological function in children with attention-deficit/hyperactivity disorder: results of a pilot study. J Child Adolesc Psychopharmacol. 2009;19:709-718.
51Treuer T, Gau SS, Méndez L, Montgomery W, Monk JA, Altin M, Wu S, Lin CC, Dueñas HJ. A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability. J Child Adolesc Psychopharmacol. 2013;23:179-193.
52Dittmann RW, Cardo E, Nagy P, Anderson CS, Bloomfield R, Caballero B, Higgins N, Hodgkins P, Lyne A, Civil R, Coghill D. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs. 2013;27:1081-1092.
53Hervas A, Huss M, Johnson M, McNicholas F, van Stralen J, Sreckovic S, Lyne A, Bloomfield R, Sikirica V, Robertson B. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial. Eur Neuropsychopharmacol. 2014;24:1861-1872.
54American Academy of Pediatrics. Subcommittee on Attention-Deficit/Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108:1033-1044.
